Omalizumab in chronic spontaneous urticaria: steroid sparing effect

References

• Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc. 2003;24:285–290.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–1414.
   PubMed Web of Science ®Google Scholar
• Generali JA, Cada DJ. Montelukast: Chronic Urticaria. Hosp Pharm. 2015;50:583–585.
   PubMedGoogle Scholar
• 21-8-2015 GAZZETTA UFFICIALE DELLA REPUBBLICA ITALIANA Serie generale - n. 193, Allegato 1.
   Google Scholar
• Gericke J, Ohanyan T, Church MK, et al. Omalizumab may not inhibit mast cell and basophil activation in vitro. J Eur Acad Dermatol Venereol. 2015;29:1832–1836.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Gime nez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72:519–533.
   PubMed Web of Science ®Google Scholar
• MacGlashan DW, Jr, Bochner BS, Adelman DC, et al. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438–1445.
   PubMed Web of Science ®Google Scholar
• Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics. 2017;7:1266–1276.
   PubMed Web of Science ®Google Scholar
• Saini SSRK, Hsieh HJ, Sterba PM, et al. Whole blood histamine concentration response to omalizumab in patients with chronic idiopathic/spontaneous urticaria: post hoc analysis of ASTERIA I, ASTERIA II and GLACIAL studies. J Allergy Clin Immunol. 2014;133:AB117.
   Web of Science ®Google Scholar
• Konstantinou GN, Asero R, Ferrer M, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2013;68:27–36.
   PubMed Web of Science ®Google Scholar
• Altrichter S, Peter HJ, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase – a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6:e14794.
   PubMed Web of Science ®Google Scholar
• Marone G, Casolaro V, Paganelli R, et al. IgG anti-IgE from atopic dermatitis induces mediator release from basophils and mast cells. J Invest Dermatol. 1989;93:246–252.
   PubMed Web of Science ®Google Scholar
• Valenta R, Mittermann I, Werfel T, et al. Linking allergy to autoimmune disease. Trends Immunol. 2009;30:109–116.
   PubMed Web of Science ®Google Scholar
• Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of FceRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest. 1995;96:2606–2612.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569–573.
   PubMed Web of Science ®Google Scholar
• Eggel A, Baravalle G, Hobi G, et al. Accelerated dissociation of IgE-FceRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014;133:1709–1719.
   PubMed Web of Science ®Google Scholar
• Takahagi S, Mihara S, Iwamoto K, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy. 2010;65:649–656.
   PubMed Web of Science ®Google Scholar
• Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in CSU patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73:705–712.
   PubMed Web of Science ®Google Scholar
• Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059–1061.e1.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–109.
   PubMed Web of Science ®Google Scholar
• Asero R, Casalone R, Iemoli E. Extraordinary response to omalizumab in a child with severe chronic urticaria. Eur Ann Allergy Clin Immunol. 2014;46:41–42.
   PubMedGoogle Scholar
• Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013;110:113–117.
   PubMed Web of Science ®Google Scholar
• Silva PM, Costa AC, Mendes A, et al. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr). 2015;43:168–173.
   PubMed Web of Science ®Google Scholar
• Al-Ahmad M. Long-term efficacy of omalizumab in patients with treatment-resistant chronic spontaneous urticaria. J Allergy Clin Immunol. 2015; 135:AB128.
   Web of Science ®Google Scholar
• Fiorino I, Loconte F, Rucco AS, et al. Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases. Postep Derm Alergol. 2014;XXXI:332–334.
   Google Scholar
• Metz M, Ohanyan T, Church MK, et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57–62.
   PubMed Web of Science ®Google Scholar
• Har D, Patel S, Khan DA, et al. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol. 2015;115:126–129.
   PubMed Web of Science ®Google Scholar
• Ensina LF, Rodrigues S, Juliani AP, et al. Omalizumab in chronic spontaneous urticaria: a Brazilian real-life experience. Int Arch Allergy Immunol. 2016;169:121–124.
   PubMed Web of Science ®Google Scholar
• Pinto Gouveia M, Gameiro A, Pinho A, et al. Long-term management of chronic spontaneous urticaria with omalizumab. Clin Exp Dermatol. 2017;42:735–742.
   PubMed Web of Science ®Google Scholar
• Sussman G, Hébert J, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014; 112:70e174.
   Web of Science ®Google Scholar
• Ensina LF, de Lacerda AE, Machado LM, et al. Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience. Ann Allergy Asthma Immunol. 2015;115:536.
   PubMed Web of Science ®Google Scholar
• Mauer M, Kaplan A, Rosen K, et al. The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol. 2018;141:1138–1139.e7.
   PubMed Web of Science ®Google Scholar
• Pisu M, James N, Sampsel S, et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:781–788.
   PubMed Web of Science ®Google Scholar